Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00808132 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,886
- Enrollment target
NCT00808132 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,886 participants.
The verdict
NCT00808132, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,886 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the safety and effectiveness of this investigational drug for the treatment of menopausal symptoms while protecting the endometrium (uterine lining) and preventing postmenopausal osteoporosis. Subject participation will last approximately 14.5 months.
Interventions
- DRUG Placebo
- DRUG bazedoxifene 20 mg/ conjugated estrogens 0.45 mg
- DRUG bazedoxifene 20 mg/ conjugated estrogens 0.625 mg
- DRUG bazedoxifene 20 mg
- DRUG conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,886 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00808132
The ClinicalTrials.gov registry entry for NCT00808132 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,886 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00808132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00808132 about?
NCT00808132 is a clinical study titled "Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis". The purpose of this research study is to evaluate the safety and effectiveness of this investigational drug for the treatment of menopausal symptoms while protecting the endometrium (uterine lining) and preventing postmenopausal osteoporosis. Subject participation will last approximately 14.5 months...
What is the current status of trial NCT00808132?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,886 participants. The study started on 2009-01. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00808132?
The interventions under investigation include: Placebo (DRUG), bazedoxifene 20 mg/ conjugated estrogens 0.45 mg (DRUG), bazedoxifene 20 mg/ conjugated estrogens 0.625 mg (DRUG), bazedoxifene 20 mg (DRUG), conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg (DRUG).
Who is sponsoring clinical trial NCT00808132?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.